ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

AGC will acquire an AstraZeneca biologics plant in Colorado

by Rick Mullin
June 5, 2020 | APPEARED IN VOLUME 98, ISSUE 22

 

AGC Biologics is acquiring an idle AstraZeneca biologic drug manufacturing facility in Boulder, Colorado. The plant includes two 20,000 L stainless steel mammalian cell bioreactors and sits on 8 hectares of land, which “provides opportunities for further expansions,” AGC says. The Japanese firm has been ramping up its contract manufacturing business, announcing plans to spend about $20 million to expand biologics facilities in Seattle and Copenhagen. It recently announced a $25 million investment in its pharmaceutical chemical plant in Spain.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment